InMed Pharmaceuticals is a biotechnology business based in the US. InMed Pharmaceuticals shares (INM) are listed on the NASDAQ and all prices are listed in US Dollars. InMed Pharmaceuticals employs 13 staff and has a trailing 12-month revenue of around $5.6 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.28 |
|---|---|
| 52-week range | $0.21 - $1.32 |
| 50-day moving average | $0.27 |
| 200-day moving average | $0.37 |
| Wall St. target price | $20.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.54 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.281 from 2024-07-25
| 1 week (2024-07-19) | 6.16% |
|---|---|
| 1 month (2024-06-26) | 6.84% |
| 3 months (2024-04-26) | 22.17% |
| 6 months (2024-01-26) | -22.91% |
| 1 year (2023-07-26) | -75.13% |
|---|---|
| 2 years (2022-07-26) | -21.94% |
| 3 years (2021-07-26) | 2.51 |
| 5 years (2019-07-22) | N/A |
| Revenue TTM | $5.6 million |
|---|---|
| Gross profit TTM | $1.4 million |
| Return on assets TTM | -29.56% |
| Return on equity TTM | -51.73% |
| Profit margin | -108.01% |
| Book value | $1.75 |
| Market Capitalization | $2.4 million |
TTM: trailing 12 months
We're not expecting InMed Pharmaceuticals to pay a dividend over the next 12 months.
You may also wish to consider:
InMed Pharmaceuticals's shares were split on a 1:25 basis on 6 September 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InMed Pharmaceuticals shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for InMed Pharmaceuticals shares which in turn could have impacted InMed Pharmaceuticals's share price.
Over the last 12 months, InMed Pharmaceuticals's shares have ranged in value from as little as $0.2122 up to $1.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InMed Pharmaceuticals's is 0.597. This would suggest that InMed Pharmaceuticals's shares are less volatile than average (for this exchange).
To put InMed Pharmaceuticals's beta into context you can compare it against those of similar companies.
InMed Pharmaceuticals Inc. , a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.